journal
MENU ▼
Read by QxMD icon Read
search

British Journal of Haematology

journal
https://www.readbyqxmd.com/read/28094847/increased-regulatory-t-cell-graft-content-is-associated-with-improved-outcome-in-haematopoietic-stem-cell-transplantation-a-systematic-review
#1
Sheila A Fisher, Abigail Lamikanra, Carolyn Dorée, Betty Gration, Pat Tsang, Robert D Danby, David J Roberts
Allogeneic haematopoietic stem cell transplant (HSCT) recipients are at increased risk of morbidity and mortality, often due to the development of acute or chronic graft-versus-host disease (GVHD). Low numbers or proportions of regulatory T cells (Tregs) have been reported in patients who develop GVHD. We undertook a systematic review of studies that reported the Treg composition of HSCT grafts in patients with haematological malignancies. Fourteen eligible studies were identified, eight of which stratified patients by Tregs (absolute dose or ratio to CD3+ or CD4+ cells)...
January 17, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28079251/maturation-associated-gene-expression-profiles-along-normal-human-bone-marrow-monopoiesis
#2
Fabiana V Mello, Liliane R Alves, Marcelo G P Land, Cristina Teodósio, María-Luz Sanchez, Paloma Bárcena, Rodrigo T Peres, Carlos E Pedreira, Elaine S Costa, Alberto Orfao
Human monopoiesis is a tightly coordinated process which starts in the bone marrow (BM) haematopoietic stem cell (HSC) compartment and leads to the production of circulating blood mature monocytes. Although mature monocytes/macrophages have been extensively studied in both normal or inflammatory conditions, monopoiesis has only been assessed in vitro and in vivo animal models, due to low frequency of the monocytic precursors in the normal human BM. Here we investigated the transcriptional profile along normal human BM monopoiesis...
January 12, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28060419/a-molecular-roadmap-of-definitive-erythropoiesis-from-human-induced-pluripotent-stem-cells
#3
Muhammad A Razaq, Stephen Taylor, David J Roberts, Lee Carpenter
Human induced pluripotent stem cells (hiPSCs) are being considered for use in understanding haematopoietic disorders and as a potential source of in vitro manufactured red cells. Here, we show that hiPSCs are able to recapitulate various stages of developmental erythropoiesis. We show that primitive erythroblasts arise first, express CD31(+) with CD235a(+) , embryonic globins and red cell markers, but fail to express the hallmark red cell transcripts of adult erythropoiesis. When hiPSC-derived CD45(+) CD235a(-) haematopoietic progenitors are isolated on day 12 and further differentiated on OP9 stroma, they selectively express CD36(+) and CD235a(+) , adult erythroid transcripts for transcription factors (e...
January 6, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28055107/results-of-a-phase-i-ii-study-of-fenretinide-and-rituximab-for-patients-with-indolent-b-cell-lymphoma-and-mantle-cell-lymphoma
#4
Andrew J Cowan, Phillip A Stevenson, Ted A Gooley, Shani L Frayo, George R Oliveira, Stephen D Smith, Damian J Green, Jennifer E Roden, John M Pagel, Brent L Wood, Oliver W Press, Ajay K Gopal
Fenretinide, a synthetic retinoid, induces apoptotic cell death in B-cell non-Hodgkin lymphoma (B-NHL) and acts synergistically with rituximab in preclinical models. We report results from a phase I-II study of fenretinide with rituximab for B-NHLs. Eligible diagnoses included indolent B-NHL or mantle cell lymphoma. The phase I design de-escalated from fenretinide at 900 mg/m(2) PO BID for days 1-5 of a 7-day cycle. The phase II portion added 375 mg/m(2) IV rituximab weekly on weeks 5-9 then every 3 months...
January 5, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28032335/eradication-of-minimal-residual-disease-improves-overall-and-progression-free-survival-in-patients-with-chronic-lymphocytic-leukaemia-evidence-from-ncrn-cll207-a-phase-ii-trial-assessing-alemtuzumab-consolidation
#5
Abraham M Varghese, Dena R Howard, Christopher Pocock, Andy C Rawstron, George Follows, Helen McCarthy, Claire Dearden, Christopher Fegan, Donald Milligan, Alexandra F Smith, Walter Gregory, Peter Hillmen
With immunochemotherapy, remission duration and survival in patients with chronic lymphocytic leukaemia is dependent on the level of minimal residual disease (MRD) after treatment. This phase II trial assessed alemtuzumab consolidation post-chemotherapy in patients who responded with persistent low levels of detectable disease. Blood was screened for MRD using multi-parameter flow cytometry, 6-24 months post-chemotherapy. MRD-positive participants received alemtuzumab 30 mg subcutaneously 3 times weekly for 6 weeks...
December 29, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/28025838/hodgkin-lymphoma-is-there-really-a-need-for-interim-and-end-of-treatment-fdg-pet-evaluations
#6
LETTER
Hugo J A Adams, Thomas C Kwee
No abstract text is available yet for this article.
December 26, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/28025836/stat3-mutations-are-not-sufficient-to-induce-large-granular-lymphocytic-leukaemia-in-mice
#7
LETTER
Avik Dutta, Dongqing Yan, Robert E Hutchison, Golam Mohi
No abstract text is available yet for this article.
December 26, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/28025833/inhibition-of-chk1-and-wee1-as-a-new-therapeutic-approach-in-diffuse-large-b-cell-lymphomas-with-myc-deregulation
#8
LETTER
Valentina Restelli, Micaela Vagni, Alberto J Arribas, Francesco Bertoni, Giovanna Damia, Laura Carrassa
No abstract text is available yet for this article.
December 26, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/28025822/the-experience-of-the-international-consortium-on-acute-promyelocytic-leukemia-in-monitoring-minimal-residual-disease-in-acute-promyelocytic-leukaemia
#9
LETTER
Ana P Lange, Ana S Lima, Antonio R Lucena-Araujo, Rafael H Jácomo, Raul A Melo, Rosane I Bittencourt, Ricardo Pasquini, Katia Pagnano, Evandro M Fagundes, Maria L Chauffaille, Carlos S Chiattone, Miguel A Sanz, Francesco Lo-Coco, David Grimwade, Eduardo M Rego
No abstract text is available yet for this article.
December 26, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/28009056/guidelines-for-the-use-of-platelet-transfusions
#10
LETTER
Lise J Estcourt, Janet Birchall, Shubha Allard, Stephen J Bassey, Peter Hersey, Jonathan Paul Kerr, Andrew D Mumford, Simon J Stanworth, Hazel Tinegate
No abstract text is available yet for this article.
December 23, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/28005293/the-diagnosis-and-management-of-primary-autoimmune-haemolytic-anaemia
#11
LETTER
Quentin A Hill, Robert Stamps, Edwin Massey, John D Grainger, Drew Provan, Anita Hill
No abstract text is available yet for this article.
December 22, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/28005265/phase-2-study-of-tabalumab-a-human-anti-b-cell-activating-factor-antibody-with-bortezomib-and-dexamethasone-in-patients-with-previously-treated-multiple-myeloma
#12
Noopur S Raje, Philippe Moreau, Evangelos Terpos, Lotfi Benboubker, Norbert Grząśko, Sarah A Holstein, Albert Oriol, Shang-Yi Huang, Meral Beksac, Kazimierz Kuliczkowski, Datchen F Tai, James E Wooldridge, Ilaria Conti, Christopher J Kaiser, Tuan S Nguyen, Damien M Cronier, Antonio Palumbo
In this double-blind, Phase 2 study, 220 patients with relapsed/refractory multiple myeloma were randomly assigned 1:1:1 to receive placebo (N = 72), tabalumab 100 mg (N = 74), or tabalumab 300 mg (N = 74), each in combination with dexamethasone 20 mg and subcutaneous bortezomib 1·3 mg/m(2) on a 21-day cycle. No significant intergroup differences were observed among primary (median progression-free survival [mPFS]) or secondary efficacy outcomes. The mPFS was 6·6, 7·5 and 7·6 months for the tabalumab 100, 300 mg and placebo groups, respectively (tabalumab 100 mg vs...
December 22, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27992065/acute-megakaryoblastic-leukaemia-light-microscopy-and-scanning-electron-microscopy-of-blast-cells
#13
Teruschka Chetty, Ntsakisi I Masingi, Zaheer Laher, Etheresia Pretorius
No abstract text is available yet for this article.
December 19, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27992063/rb-but-not-r-hcvad-is-a-feasible-induction-regimen-prior-to-auto-hct-in-frontline-mcl-results-of-swog-study-s1106
#14
Robert W Chen, Hongli Li, Steven H Bernstein, Samir Kahwash, Lisa M Rimsza, Stephen J Forman, Louis Constine, Thomas C Shea, Amanda F Cashen, Kristie A Blum, Timothy S Fenske, Paul M Barr, Tycel Phillips, Michael Leblanc, Richard I Fisher, Bruce D Cheson, Sonali M Smith, Malek Faham, Jennifer Wilkins, John P Leonard, Brad S Kahl, Jonathan W Friedberg
Aggressive induction chemotherapy followed by autologous haematopoietic stem cell transplant (auto-HCT) is effective for younger patients with mantle cell lymphoma (MCL). However, the optimal induction regimen is widely debated. The Southwestern Oncology Group S1106 trial was designed to assess rituximab plus hyperCVAD/MTX/ARAC (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate) (RH) versus rituximab plus bendamustine (RB) in a randomized phase II trial to select a pre-transplant induction regimen for future development...
December 19, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27991657/molecular-typing-for-blood-group-antigens-within-40%C3%A2-min-by-direct-polymerase-chain-reaction-from-plasma-or-serum
#15
Franz F Wagner, Willy A Flegel, Rita Bittner, Andrea Döscher
Determining blood group antigens by serological methods may be unreliable in certain situations, such as in patients after chronic or massive transfusion. Red cell genotyping offers a complementary approach, but current methods may take much longer than conventional serological typing, limiting their utility in urgent situations. To narrow this gap, we devised a rapid method using direct polymerase chain reaction (PCR) amplification while avoiding the DNA extraction step. DNA was amplified by PCR directly from plasma or serum of blood donors followed by a melting curve analysis in a capillary rapid-cycle PCR assay...
December 19, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27984647/pathology-findings-in-patients-with-cutaneous-t-cell-lymphomas-treated-with-allogeneic-haematopoietic-stem-cell-transplantation
#16
LETTER
Thomas Menter, Hanine Medani, Eduardo Olavarria, Edward Kanfer, Kikkeri N Naresh
No abstract text is available yet for this article.
December 16, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27984644/li-fraumeni-syndrome-a-paradigm-for-the-understanding-of-hereditary-cancer-predisposition
#17
REVIEW
Jessica M Valdez, Kim E Nichols, Chimene Kesserwan
Li-Fraumeni syndrome (LFS) is a rare cancer predisposing condition caused by germline mutations in TP53, the gene encoding the TP53 transcription factor. LFS is typified by the development of a wide spectrum of childhood and adult-onset malignancies, which includes, among others, the lymphoid and myeloid leukaemias, myelodysplastic syndrome and, to a lesser extent, lymphoma. Accordingly, it is important that haematologists/oncologists be familiar with this pleiotropic hereditary cancer syndrome. The high cancer risk and variability in type and age of cancer onset have raised questions about the underlying biology and optimal treatment approaches for individuals with LFS...
December 16, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27984643/brentuximab-vedotin-and-bendamustine-produce-high-complete-response-rates-in-patients-with-chemotherapy-refractory-hodgkin-lymphoma
#18
LETTER
Matko Kalac, Jennifer K Lue, Emily Lichtenstein, Ithamar Turenne, Celeste Rojas, Jennifer E Amengual, Ahmed Sawas, Changchun Deng, Markus Y Mapara, Joseph M Connors, John Kuruvilla, Owen A O'Connor
No abstract text is available yet for this article.
December 16, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27984642/tp53-mutations-predict-decitabine-induced-complete-responses-in-patients-with-myelodysplastic-syndromes
#19
Chun-Kang Chang, You-Shan Zhao, Feng Xu, Juan Guo, Zheng Zhang, Qi He, Dong Wu, Ling-Yun Wu, Ji-Ying Su, Lu-Xi Song, Chao Xiao, Xiao Li
To identify the molecular signatures that predict responses to decitabine (DAC), we examined baseline gene mutations (28 target genes) in 109 myelodysplastic syndrome (MDS) patients at diagnosis. We determined that TP53 mutations predicted complete response (CR), as 10 of 15 patients (66·7%) who possessed TP53 mutations achieved a CR. Univariate and multivariate analyses showed that TP53 mutations are the only molecular signatures predictive of a CR to DAC in MDS. Among the ten patients with TP53 mutations who achieved a CR, nine presented with complex karyotypes due to abnormalities involving chromosome 5 and/or chromosome 7, and eight possessed monosomies...
December 16, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27984641/csf3r-t618i-asxl1-g942%C3%A2-fs-and-stat5b-n642h-trimutation-co-contribute-to-a-rare-chronic-neutrophilic-leukaemia-manifested-by-rapidly-progressive-leucocytosis-severe-infections-persistent-fever-and-deep-venous-thrombosis
#20
LETTER
Qianhui Luo, Jiankai Shen, Yuan Yang, Haiyan Tang, Meng Shi, Jun Liu, Zhonghua Liu, Xiaoliu Shi, Yan Yi
No abstract text is available yet for this article.
December 16, 2016: British Journal of Haematology
journal
journal
20057
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"